Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research

Stephanie R. Land, Benjamin A. Toll, Carol M. Moinpour, Sandra A. Mitchell, Jamie S. Ostroff, Dorothy K. Hatsukami, Sonia A. Duffy, Ellen R. Gritz, Nancy A. Rigotti, Thomas H. Brandon, Sheila A. Prindiville, Linda P. Sarna, Robert A. Schnoll, Roy S. Herbst, Paul M. Cinciripini, Scott J. Leischow, Carolyn M. Dresler, Michael C. Fiore, Graham W. Warren

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

There is strong evidence that cigarette smoking causes adverse outcomes in people with cancer. However, more research is needed regarding those effects and the effects of alternative tobacco products and of secondhand smoke, the effects of cessation (before diagnosis, during treatment, or during survivorship), the biologic mechanisms, and optimal strategies for tobacco dependence treatment in oncology. Fundamentally, tobacco is an important source of variation in clinical treatment trials. Nevertheless, tobacco use assessment has not been uniform in clinical trials. Progress has been impeded by a lack of consensus regarding tobacco use assessment suitable for cancer patients. The NCI-AACR Cancer Patient Tobacco Use Assessment Task Force identified priority research areas and developed recommendations for assessment items and timing of assessment in cancer research. A cognitive interview study was conducted with 30 cancer patients at the NIH Clinical Center to evaluate and improve the measurement items. The resulting Cancer Patient Tobacco Use Questionnaire (C-TUQ) includes Core items for minimal assessment of tobacco use at initial and follow-up time points, and an Extension set. Domains include the following: cigarette and other tobacco use status, intensity, and past use; use relative to cancer diagnosis and treatment; cessation approaches and history; and secondhand smoke exposure. The Task Force recommends that assessment occur at study entry and, at a minimum, at the end of protocol therapy in clinical trials. Broad adoption of the recommended measures and timing protocol, and pursuit of the recommended research priorities, will help us to achieve a clearer understanding of the significance of tobacco use and cessation for cancer patients.

Original languageEnglish (US)
Pages (from-to)1907-1913
Number of pages7
JournalClinical Cancer Research
Volume22
Issue number8
DOIs
StatePublished - Apr 15 2016

Fingerprint

Tobacco Use
Research
Neoplasms
Tobacco Smoke Pollution
Clinical Trials
Advisory Committees
Tobacco Products
Tobacco Use Cessation
Therapeutics
Tobacco Use Disorder
Tobacco
Consensus
Survival Rate
Smoking
History
Interviews

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Land, S. R., Toll, B. A., Moinpour, C. M., Mitchell, S. A., Ostroff, J. S., Hatsukami, D. K., ... Warren, G. W. (2016). Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clinical Cancer Research, 22(8), 1907-1913. https://doi.org/10.1158/1078-0432.CCR-16-0104

Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. / Land, Stephanie R.; Toll, Benjamin A.; Moinpour, Carol M.; Mitchell, Sandra A.; Ostroff, Jamie S.; Hatsukami, Dorothy K.; Duffy, Sonia A.; Gritz, Ellen R.; Rigotti, Nancy A.; Brandon, Thomas H.; Prindiville, Sheila A.; Sarna, Linda P.; Schnoll, Robert A.; Herbst, Roy S.; Cinciripini, Paul M.; Leischow, Scott J.; Dresler, Carolyn M.; Fiore, Michael C.; Warren, Graham W.

In: Clinical Cancer Research, Vol. 22, No. 8, 15.04.2016, p. 1907-1913.

Research output: Contribution to journalArticle

Land, SR, Toll, BA, Moinpour, CM, Mitchell, SA, Ostroff, JS, Hatsukami, DK, Duffy, SA, Gritz, ER, Rigotti, NA, Brandon, TH, Prindiville, SA, Sarna, LP, Schnoll, RA, Herbst, RS, Cinciripini, PM, Leischow, SJ, Dresler, CM, Fiore, MC & Warren, GW 2016, 'Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research', Clinical Cancer Research, vol. 22, no. 8, pp. 1907-1913. https://doi.org/10.1158/1078-0432.CCR-16-0104
Land, Stephanie R. ; Toll, Benjamin A. ; Moinpour, Carol M. ; Mitchell, Sandra A. ; Ostroff, Jamie S. ; Hatsukami, Dorothy K. ; Duffy, Sonia A. ; Gritz, Ellen R. ; Rigotti, Nancy A. ; Brandon, Thomas H. ; Prindiville, Sheila A. ; Sarna, Linda P. ; Schnoll, Robert A. ; Herbst, Roy S. ; Cinciripini, Paul M. ; Leischow, Scott J. ; Dresler, Carolyn M. ; Fiore, Michael C. ; Warren, Graham W. / Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 8. pp. 1907-1913.
@article{14013e1a70724aa086917be6c05815f8,
title = "Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research",
abstract = "There is strong evidence that cigarette smoking causes adverse outcomes in people with cancer. However, more research is needed regarding those effects and the effects of alternative tobacco products and of secondhand smoke, the effects of cessation (before diagnosis, during treatment, or during survivorship), the biologic mechanisms, and optimal strategies for tobacco dependence treatment in oncology. Fundamentally, tobacco is an important source of variation in clinical treatment trials. Nevertheless, tobacco use assessment has not been uniform in clinical trials. Progress has been impeded by a lack of consensus regarding tobacco use assessment suitable for cancer patients. The NCI-AACR Cancer Patient Tobacco Use Assessment Task Force identified priority research areas and developed recommendations for assessment items and timing of assessment in cancer research. A cognitive interview study was conducted with 30 cancer patients at the NIH Clinical Center to evaluate and improve the measurement items. The resulting Cancer Patient Tobacco Use Questionnaire (C-TUQ) includes Core items for minimal assessment of tobacco use at initial and follow-up time points, and an Extension set. Domains include the following: cigarette and other tobacco use status, intensity, and past use; use relative to cancer diagnosis and treatment; cessation approaches and history; and secondhand smoke exposure. The Task Force recommends that assessment occur at study entry and, at a minimum, at the end of protocol therapy in clinical trials. Broad adoption of the recommended measures and timing protocol, and pursuit of the recommended research priorities, will help us to achieve a clearer understanding of the significance of tobacco use and cessation for cancer patients.",
author = "Land, {Stephanie R.} and Toll, {Benjamin A.} and Moinpour, {Carol M.} and Mitchell, {Sandra A.} and Ostroff, {Jamie S.} and Hatsukami, {Dorothy K.} and Duffy, {Sonia A.} and Gritz, {Ellen R.} and Rigotti, {Nancy A.} and Brandon, {Thomas H.} and Prindiville, {Sheila A.} and Sarna, {Linda P.} and Schnoll, {Robert A.} and Herbst, {Roy S.} and Cinciripini, {Paul M.} and Leischow, {Scott J.} and Dresler, {Carolyn M.} and Fiore, {Michael C.} and Warren, {Graham W.}",
year = "2016",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-16-0104",
language = "English (US)",
volume = "22",
pages = "1907--1913",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research

AU - Land, Stephanie R.

AU - Toll, Benjamin A.

AU - Moinpour, Carol M.

AU - Mitchell, Sandra A.

AU - Ostroff, Jamie S.

AU - Hatsukami, Dorothy K.

AU - Duffy, Sonia A.

AU - Gritz, Ellen R.

AU - Rigotti, Nancy A.

AU - Brandon, Thomas H.

AU - Prindiville, Sheila A.

AU - Sarna, Linda P.

AU - Schnoll, Robert A.

AU - Herbst, Roy S.

AU - Cinciripini, Paul M.

AU - Leischow, Scott J.

AU - Dresler, Carolyn M.

AU - Fiore, Michael C.

AU - Warren, Graham W.

PY - 2016/4/15

Y1 - 2016/4/15

N2 - There is strong evidence that cigarette smoking causes adverse outcomes in people with cancer. However, more research is needed regarding those effects and the effects of alternative tobacco products and of secondhand smoke, the effects of cessation (before diagnosis, during treatment, or during survivorship), the biologic mechanisms, and optimal strategies for tobacco dependence treatment in oncology. Fundamentally, tobacco is an important source of variation in clinical treatment trials. Nevertheless, tobacco use assessment has not been uniform in clinical trials. Progress has been impeded by a lack of consensus regarding tobacco use assessment suitable for cancer patients. The NCI-AACR Cancer Patient Tobacco Use Assessment Task Force identified priority research areas and developed recommendations for assessment items and timing of assessment in cancer research. A cognitive interview study was conducted with 30 cancer patients at the NIH Clinical Center to evaluate and improve the measurement items. The resulting Cancer Patient Tobacco Use Questionnaire (C-TUQ) includes Core items for minimal assessment of tobacco use at initial and follow-up time points, and an Extension set. Domains include the following: cigarette and other tobacco use status, intensity, and past use; use relative to cancer diagnosis and treatment; cessation approaches and history; and secondhand smoke exposure. The Task Force recommends that assessment occur at study entry and, at a minimum, at the end of protocol therapy in clinical trials. Broad adoption of the recommended measures and timing protocol, and pursuit of the recommended research priorities, will help us to achieve a clearer understanding of the significance of tobacco use and cessation for cancer patients.

AB - There is strong evidence that cigarette smoking causes adverse outcomes in people with cancer. However, more research is needed regarding those effects and the effects of alternative tobacco products and of secondhand smoke, the effects of cessation (before diagnosis, during treatment, or during survivorship), the biologic mechanisms, and optimal strategies for tobacco dependence treatment in oncology. Fundamentally, tobacco is an important source of variation in clinical treatment trials. Nevertheless, tobacco use assessment has not been uniform in clinical trials. Progress has been impeded by a lack of consensus regarding tobacco use assessment suitable for cancer patients. The NCI-AACR Cancer Patient Tobacco Use Assessment Task Force identified priority research areas and developed recommendations for assessment items and timing of assessment in cancer research. A cognitive interview study was conducted with 30 cancer patients at the NIH Clinical Center to evaluate and improve the measurement items. The resulting Cancer Patient Tobacco Use Questionnaire (C-TUQ) includes Core items for minimal assessment of tobacco use at initial and follow-up time points, and an Extension set. Domains include the following: cigarette and other tobacco use status, intensity, and past use; use relative to cancer diagnosis and treatment; cessation approaches and history; and secondhand smoke exposure. The Task Force recommends that assessment occur at study entry and, at a minimum, at the end of protocol therapy in clinical trials. Broad adoption of the recommended measures and timing protocol, and pursuit of the recommended research priorities, will help us to achieve a clearer understanding of the significance of tobacco use and cessation for cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84967316682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967316682&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0104

DO - 10.1158/1078-0432.CCR-16-0104

M3 - Article

C2 - 26888828

AN - SCOPUS:84967316682

VL - 22

SP - 1907

EP - 1913

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -